Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 15/20 | 0.73 |
| ▸ | GABRB2 | P47870 | 15/20 | 0.73 |
| ▸ | CCKAR | P32238 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437318 | 0.89 | GABRA2 (0.76) | GABRA2GABRB2PTGS2LMNATP53 | |
| SCHEMBL1438305 | 0.84 | GABRA2 (1.00) | GABRA2GABRB2PTGS2LMNATP53 | |
| SCHEMBL1764921 | 0.79 | TP53 (0.57) | GABRA2GABRB2LMNATP53 | |
| SCHEMBL1437639 | 0.79 | GABRA2 (0.77) | GABRA2GABRB2PTGS2 | |
| SCHEMBL9460158 | 0.79 | KMT2A (0.51) | GABRA2GABRB2LMNATP53 | |
| SCHEMBL2152281 | 0.78 | CCKAR (0.66) | GABRA2GABRB2CCKAR | |
| SCHEMBL2152132 | 0.78 | CCKAR (0.66) | GABRA2GABRB2CCKAR | |
| SCHEMBL6336459 | 0.78 | GABRA2 (0.69) | GABRA2GABRB2PTGS2 | |
| SCHEMBL5336123 | 0.78 | GABRA2 (0.72) | GABRA2GABRB2PTGS2 | |
| SCHEMBL6533838 | 0.78 | GABRA2 (0.72) | GABRA2GABRB2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | GABRA2 4293/4885GABRB2 4278/4885CCKAR 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.